FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The PhRMA Foundation announced the appointment to its Board of Directors of Dr. John C. Reed, MD, PhD, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson (J&J), and Dr. Donatello ...

Insilico Medicine pulls back the curtain on developmental timelines, highlighting a ~13 month average timeline to reach developmental candidate (DC) nomination across 22 programs. Insilico’s QPCTL ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...